Author

Deyaa Adib

Observed names: Adib Deyaa, D. Adib

Observed institution: Baxalta (United States)

OpenAlex ID: A5081200684

PD-011 Safety and efficacy analysis of imalumab, an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody, alone or in combination with 5-fluorouracil/leucovorin (5-FU/LV) or panitumumab, in patients with metastatic colorectal cancer (mCRC)

2016 · D. Mahalingam, M. Patel, et al. · Annals of Oncology · 21

Anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody imalumab (BAX69) in advanced solid tumors: Final results of first-in-human phase 1 study

2016 · D. Mahalingam, M.R. Patel, et al. · Annals of Oncology · 5

A randomized, open-label phase II study of nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma (mPAC).

2016 · Andrew Dean, Li-Tzong Chen, et al. · Journal of Clinical Oncology · 3

Abstract CT046: First-in-human phase 1 study assessing imalumab (BAX69), an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody in advanced solid tumors

2016 · Devalingam Mahalingam, Manish R. Patel, et al. · Cancer Research · 1

Autologous T-cell antigen coupler targeting HER2 (TAC01-HER2) in advanced or metastatic solid tumors

2026 · E.E. Dumbrava, D. Olson, et al. · Annals of Oncology

P-287 Nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine as first-line therapy in patients with metastatic pancreatic adenocarcinoma (mPAC): a randomized, open-label phase 2 study

2016 · Dean Andrew, Ramanathan Ramesh, et al. · Annals of Oncology

Works count: 6

Citation count: 30

H-index: 3

I10-index: 1